DPP-4 Inhibition and Neuroprotection: Do Mechanisms Matter?
Open Access
- 14 March 2013
- journal article
- editorial
- Published by American Diabetes Association in Diabetes
- Vol. 62 (4), 1029-1031
- https://doi.org/10.2337/db12-1794
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Cardiovascular Biology of the Incretin SystemEndocrine Reviews, 2012
- Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic ratsClinical Science, 2012
- Exendin-4, a Glucagon-Like Peptide-1 Receptor Agonist, Provides Neuroprotection in Mice Transient Focal Cerebral IschemiaJournal of Cerebral Blood Flow & Metabolism, 2011
- Neuroprotective properties of GLP-1: theoretical and practical applicationsCurrent Medical Research and Opinion, 2011
- GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and ParkinsonismProceedings of the National Academy of Sciences of the United States of America, 2009
- Glucose Control and Vascular Complications in Veterans with Type 2 DiabetesNew England Journal of Medicine, 2009
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 DiabetesNew England Journal of Medicine, 2008
- Effects of Intensive Glucose Lowering in Type 2 DiabetesNew England Journal of Medicine, 2008
- Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's diseaseJournal of Neuroinflammation, 2008
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998